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Abstract: Maternal nutritional imbalances, in addition to maternal overweight and obesity, can result
in long-term effects on the metabolic health of the offspring, increasing the risk of common non-
communicable disorders such as obesity, diabetes and cardiovascular disease. This increased disease
risk may also be transmitted across generations. Unfortunately, lifestyle interventions have shown
reduced compliancy and limited efficacy. Resveratrol is a natural polyphenolic compound reported
to have pleiotropic beneficial actions including a possible protective effect against the metabolic
programming induced by poor dietary habits during development. However, studies to date are
inconclusive regarding the potential metabolic benefits of maternal resveratrol supplementation
during pregnancy and lactation on the offspring. Moreover, the responses to metabolic challenges
are suggested to be different in males and females, suggesting that the effectiveness of treatment
strategies may also differ, but many studies have been performed only in males. Here we review
the current evidence, both in humans and animal models, regarding the possible beneficial effects
of maternal resveratrol intake on the metabolic health of the offspring and highlight the different
effects of resveratrol depending on the maternal diet, as well as the differential responses of males
and females.
Keywords: maternal resveratrol; metabolic health; offspring; programming; sex differences
1. Introduction
The developmental origins of health and disease theory emphasizes the link between
fetal and neonatal exposure to environmental factors and the development of metabolic
and other disorders later in life [1–9]. This theory indicates that maternal nutrition during
sensitive time periods of early development, prior to and during pregnancy and lactation,
can strongly impact the offspring’s health later in life. Moreover, increasing evidence
has shown that maternal nutritional imbalances, in addition to maternal overweight and
obesity, may lead to long-term effects on the metabolic health of the offspring, increasing
the risk of common non-communicable disorders and diseases such as obesity, diabetes
and cardiovascular disease [10–13] (Figure 1) and that these effects can even be transmitted
to future generations. Likewise, maternal resveratrol intake has also been shown to have
effects on both the mother and fetus, with a possible interaction between maternal nutrition
and resveratrol intake on the offspring’s long-term health, as depicted in Figure 1. Obesity
is a prevalent metabolic disorder worldwide and the fact that the maternal obesogenic
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environment can lead to cyclical transgenerational transmission could contribute substan-
tially to augmenting the obesity epidemic. Indeed, in 2016 the World Health Organization
reported that in Europe 50% of women of childbearing age and 20%–25% of pregnant
women were either overweight or obese [14]. Curtailing excessive weight gain during
pregnancy has been shown to have health benefits for both the mothers and offspring,
emphasizing that it is crucial to target all stages of development in order to reverse the
obesity trend [15]. Unfortunately, lifestyle interventions, including diet and exercise, have
shown low compliancy and limited efficacy.
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An important area of investigation in the field of nutrition and metabolism is the 
search for dietary components and supplements that improve metabolic health, and one 
compound that has received increasing attention in recent years is resveratrol (3,4′,5-tri-
hydroxystilbene). Resveratrol is a natural polyphenolic compound produced in a variety 
of plant species (i.e., grapes, peanuts, cocoa, berries) and has been shown to have anti-
inflammatory [16], antioxidant [17], anti-obesogenic [18–20], anti-atherosclerotic [21] and 
antidiabetic effects [22–24] (Figure 2). Furthermore, this polyphenol is hypothesized to be 
potentially useful in protecting against factors during development that program suscep-
tibility to metabolic syndrome [23,25,26] (Figure 2). However, different experimental 
models, as well as a wide range of doses, routes of administration and therapeutic periods, 
have led to inconclusive results regarding the potential metabolic benefits of maternal 
resveratrol supplementation during pregnancy and lactation [27]. Moreover, the re-
sponses to various metabolic challenges have been shown to be different in males and 
females [28–32] and this might suggest that the effectiveness of treatment strategies may 
also differ. Not only is there a sex difference in weight gain and adipose tissue accumula-
tion and distribution in response to increased energy intake, but the secondary complica-
tions due to being overweight or obese also differ between males and females [33]. Unfor-
tunately, little is known regarding whether long-term metabolism is affected differently 
Figure 1. Possible program ing effects of maternal nutritio al i bala ce uring fetal and perinatal life and the potential
beneficial effects of resveratrol.
An important area of investigation in the field of nutrition and metabolism is the
search for dietary components and supplements that improve metabolic health, and one
compound that has received increasing attention in recent years is resveratrol (3,4′,5-
trihydroxystilbene). Resveratrol is a natural polyphenolic compound produced in a variety
of plant species (i.e., grapes, peanuts, cocoa, berries) and has been shown to have anti-
inflammatory [16], antioxidant [17], anti-obesogenic [18–20], anti-atherosclerotic [21] and
antidiabetic effects [22–24] (Figure 2). Furthermore, this polyphenol is hypothesized to be
potentially useful in protecting against factors during development that program suscepti-
bility to metabolic syndrome [23,25,26] (Figure 2). However, different experimental models,
as well as a wide range of doses, routes of administration and therapeutic periods, have led
to inconclusive results regarding the potential metabolic benefits of maternal resveratrol
supplementation during pregnancy and lactation [27]. Moreover, the responses to various
metabolic challenges have been shown to be different in males and females [28–32] and
this might suggest that the effectiveness of treatment strategies may also differ. Not only is
there a sex difference in weight gain and adipose tissue accumulation and distribution in
response to increased energy intake, but the secondary complications due to being over-
weight or obese also differ between males and females [33]. Unfortunately, little is known
regarding whether long-term metabolism is affected differently in males and females in
response to specific nutritional changes, including resveratrol intake, during early life.
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term effects on the metabolic health of the child, including an increased risk of obesity, 
diabetes and cardiovascular disease [36,38]. This indicates that modification of the nutri-
tional supply to the fetus and newborn offers a window of opportunity to improve meta-
bolic homeostasis of the offspring in later life, with effects on the hypothalamic–adipose 
axis and leptin signaling hypothesized to play a central role in this process [4,39]. 
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Here we review the current evidence, both in humans and animal mod ls, regarding
the possible b neficial effects of maternal resveratrol intake on the metabolic health of the
offspri g. We have highlighted the differential effects of r sveratrol de e ding n the
maternal diet, as well as th differences between males and females in response to both
dietary challenges and resveratrol.
2. Metabolic Effects of Maternal Nutritional Imbalances
In support of the d v lopmental origins of health and disease theory, animal models
and human studies have demonstr ted that early environmental infl ences, including
nutritional facto s, c affect adult metabolic homeostasis [34–37]. Indeed, unbalanced
nutrition duri g pregn ncy and lactation as been show to induce both short- and
long-term effects on the metabolic health of the child, including an i creased risk of
obesity, diabetes and cardiovascular disease [36,38]. This indicates that modification of the
nutritional supply to the fetus and newborn offers a window of opportunity to improve
metabolic homeostasis of the offspring in later life, with effects on the hypothalamic–
adipose axis and leptin signaling hypothesized to play a central role in this process [4,39].
2.1. Experimental Animal Studies
In experimental animal studies, maternal overnutrition and obesity increase the inci-
dence of obesity in the offspring, with unfavorable programming of the appetite-regulating
system in the hypothalamus shown to be involved [28,40]. Consistent with this, central
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leptin resistance has been observed in offspring from overfed or obese rodent mothers,
as demonstrated by higher hypothalamic suppressor of cytokine signaling 3 (SOCS3)
activation and blunted downstream signaling of leptin [40,41]. It is important to note
that in rodents the initial postnatal weeks are critical for the formation of hypothalamic
neurocircuits, with approximately postnatal day (PND) 20 being the end of the sensitive
period for hypothalamic differentiation and development [41]. Tsai et al. showed leptin
dysregulation, as indicated by an increase in plasma leptin/soluble leptin receptor (sOB-R)
ratio, and increased retroperitoneal adiposity in adult male offspring from high-fat fed
mothers [13].
Other maternal nutritional imbalances, such as a high-fat/high-sucrose diet during
gestation, have been shown to affect the hepatic lipid profile in the offspring at 4 weeks of
age, with some sex-specific effects [42]. Moreover, in rodents high-fructose consumption
by dams during pregnancy and lactation are reported to led to sex-specific developmental
programming of the metabolic syndrome phenotype in adult offspring, with this being
more pronounced in males than in females [43]. Maternal high-fructose diet during
gestation and lactation also impairs learning and memory performance in a sex-specific
manner, due at least in part to an epigenetic mechanism of increased histone deacetylase 4
(HDAC 4) activity and suppression of neurogenesis in the hippocampus, with adult female
offspring being more affected [12]. A maternal high-fructose diet is also reported to initiate
neuro-inflammation in the hippocampus of adult female offspring [44]. A recent review
analyzes the negative programming effects of maternal obesity, both in animal models
and humans, emphasizing the five major mechanisms implicated to date: the gut–brain
axis, inflammation, mitochondrial dysfunction, brain-derived neurotrophic factors and
epigenomic effects [26].
Mal-programming of metabolism also occurs with maternal subnutrition. For example,
in rodents maternal food restriction (50% caloric restriction during gestational days 12.5 to
18.5) was found to significantly decrease glucose tolerance in adult offspring, as well as to
increase lipogenic gene expression in adipose tissue and adipocyte size [45]. Furthermore,
a maternal low-protein diet can lead to lower birth weight, impaired glucose tolerance,
and decreased fasting serum insulin levels in offspring at weaning [46]. Thus, it is not only
overnutrition, but also insufficient or poor nutrition that determine future metabolic health
of the offspring.
2.2. Studies in Humans
Consistent with animal studies, numerous epidemiological studies in humans have
shown that metabolic programming of energy balance can be attributed to events during
the very early stages of development [47,48]. In contrast to rodents, the sensitive period
for metabolic programming in humans occurs predominantly in utero, during the third
trimester of gestation, as well as the early neonatal period [49]. In line with this, maternal
undernutrition during pregnancy and lactation has been shown to significantly increase the
risks of metabolic syndrome, non-alcoholic fatty liver disease, and visceral fat deposition
and dysfunction in the adult offspring [47,48,50,51]. Famine is a natural model for inves-
tigating the effects of an early-life poor nutritional environment on energy homeostasis
in later life. One well known example of this is the Dutch winter famine (1944–1945)
where maternal undernutrition during pregnancy was associated with higher prevalence
of diabetes and disorders of lipid profiles, glucose intolerance and insulin resistance in
adult offspring aged 50–59, with the outcome depending on both the gestational period
when exposed to famine and the offspring’s sex [35,50,51]. For example, Lumey et al.,
found an association between maternal undernutrition and increased total cholesterol and
triglycerides, but only in females [51].
In humans, maternal obesity during pregnancy and lactation is one of the most typical
examples of early-life overnutrition that has been linked to increased risks of metabolic
disorders in the offspring [36,38,52–54]. A growing body of evidence indicates independent
associations between maternal obesity, excessive weight gain, as well as diet during preg-
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nancy and lactation, with childhood adiposity and cardiovascular risk indicators [36,38]. It
is important to emphasize that not only obesity, but also weight gain is of importance as
an increase in gestational weight gain has been shown to be an independent predictor for
increased body mass index (BMI), adiposity and cardiovascular risks in the offspring [54].
Accordingly, a meta-analyses recently identified a dose-response association between ma-
ternal BMI and childhood obesity of the offspring, with maternal obesity or overweight
increasing the odds of obesity in the child by 264% and 89%, respectively [55]. There is also
a well-established relationship between micronutrient deficiencies and fetal development
and childhood health with the early Nutrition Research Project emphasizing the impor-
tance of nutrition and lifestyle before and during pregnancy, as well as during lactation
and infancy [36].
There is strong evidence, both in experimental animal models and human studies, sup-
porting the detrimental effects of an unbalanced maternal diet on the offspring’s metabolic
health. This emphasizes the fact that the periods of gestation and lactation offer important
opportunities to improve metabolic health in the offspring and that strategies against obe-
sity should not only take into consideration interventions in adulthood, but should begin
very early in life, including during the fetal and neonatal periods [15]. However, much
more information is needed regarding how early metabolic programming is influenced by
macronutrients, as well as by specific micronutrients and bioactive compounds.
3. Effects of Resveratrol
The beneficial effects of specific dietary bioactive compounds such as resveratrol on en-
ergy metabolism during postnatal life have been reported by different authors [24,35,56,57].
For example, Franco et al. showed that resveratrol (30 mg/kg/d), administered from
150 PND to 180 PND, reduced the increase in body weight, hyperphagia, visceral obesity,
hyperleptinemia, hyperglycemia, insulin resistance and hypoadiponectinemia induced by
an experimental model of early weaning in rats [18]. These same authors also reported
that in adult offspring of mothers fed a HFD, postnatal resveratrol treatment completely
normalized the hyperleptinemia and increases p-STAT3 levels in the hypothalamus, [58]
suggesting that this compound improves at least some of the adverse effects of maternal
HFD on leptin signaling.
Given the protective effects of postnatal resveratrol intake and its capacity to cross
the placenta, along with its lack of teratogenicity as reported in most studies, the effects
of maternal resveratrol supplementation during gestation and/or lactation on the dams
and their offspring’s health has become a point of interest [23,25,26,59]. Indeed, the
unbalanced redox state induced by factors that result in poor metabolic outcome in the
offspring indicates a potential mechanism by which perinatal resveratrol could be beneficial
due to its antioxidant capacity. Although several bioactive redox modulators have been
proposed for use during gestation and pregnancy, resveratrol has attracted the most
interest. Studies have confirmed a link between molecular targets and signaling pathways
of resveratrol [i.e., sirtuin 1 (SIRT1), 5′ adenosine monophosphate-activated protein kinase
(AMPK), estrogen receptor α (ERα) and mammalian target of rapamycin (mTOR)] and
the physiopathology of metabolic syndrome-related disorders [60] that could help to shed
light on the mechanisms underlying metabolic syndrome, as well as those involved in
establishing long-term metabolic health and potential targets for its improvement.
3.1. Animal Studies
Various studies in experimental animal models support the hypothesis that maternal
resveratrol intake exerts beneficial effects on the offspring’s metabolic health [13,29–31,61–68]
(Table 1). Different early life insults, such as maternal gestational diabetes (MGD), obesity
and nutritional imbalances, have been used to study the potential protective effects of
resveratrol. As summarized in Table 1, the most commonly used experimental models for
these studies involve rodents [13,29–31,61,65–69]. However, in an attempt to approximate
human physiology, some studies have also been performed in nonhuman primates [62–64].
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Table 1. Experimental studies in pregnant animal models supplemented with resveratrol. AMPK: 5′ adenosine
monophosphate-activated protein kinase. BAT: brown adipose tissue. BW: body weight. CD: control diet. DHA: do-
cosahexanoic acid. ED: embryonic day. F: female. FAT: fat mass. GD: gestational day. Gest: gestation. HFD: high-fat
diet. HFHS: high-fat high-sucrose diet. HMGCR: hydroxy-3-methylglutaryl-CoA reductase. Hth Hyperlep: hypothalamic
hyperleptinemia. Lact: lactation. LFD: low-fat diet. LPD: low-protein diet. M: male. NS: not specified. PND: postnatal
day. Preg: pregnancy. RPT: retroperitoneal tissue. ROS: reactive oxygen species. SCAT: subcutaneous adipose tissue. S-D:
Sprague Dawley. SIRT1: Sirtuin 1; STZ: streptozotocin. TG: triglycerides. VAT: visceral adipose tissue. W: weeks. WAT:
white adipose tissue. Wi: Wistar rat. WD: Western diet. * Genetic gestational diabetes model C57BL/KsJ-Lepdb/+ (db/+).
** C57BL/Gj mice. ↓ decreases, ↑ increases.
Model Species/Sex Resveratrol Doseand Route Time Age at Outcome Offspring Outcome Reference
Maternal diabetes Rat (S-D)/NS 100 mg/BW/d 3–12 d GA ED 12 ↓ oxidative stressand apoptosis [61]
Maternal diabetes GDM mouse*/NS 10 mg/BW/d
4 w pre-preg.
and gest. PND 1 ↓ BW and ↑ AMPK [68]
Maternal
diabetes Rat (Wi)/NS 100 mg/BW/d Gestation (8–12 d) GD 19 ↓ oxidative stress [65]
Maternal




TG and ROS [29]






drinking water Preg to PND21 PND 21
Sex differences
↓BW, Lept, VAT, SCAT [30]




drinking water Preg to PND21 PND 180
↓BW, adiposity
regulates SIRT 1 in RPT
Lipid modulation
[70]










drinking water Preg to PND21 PND 150
VAT ↓in HFD↑ in LFD
↑ VAT adipocyte size [31]
Maternal WD Japanesemacaque/NS +0.37% in WD 3m pre-G to 130 GA ED130
↓ liver lipid and
placental inflammation [62]




macaque/NS 0.37% in WD 3m pre-G to 130 GA ED 130
↑ Placental fatty acid
uptake (DHA) [64]
There is evidence supporting the beneficial health properties of maternal resveratrol
from studies performed in embryos and fetuses. In Sprague Dawley rats, maternal resver-
atrol intake (100 mg/BW/day) during gestation [(from embryonic day (ED) 3 to ED12]
was shown to prevent embryonic oxidative stress and apoptosis associated with diabetic
embryopathy [61]. These authors also found that resveratrol significantly suppressed
the activation of caspases in 12-day embryos of diabetic dams. In a genetic MGD mouse
model (C57BL/KsJ-Lepdb/+), maternal resveratrol (10 mg/kg/day) was found to reduce
gestational diabetes mellitus symptoms in pregnant female mice and improved offspring
development, through reducing the enzymatic capacity for glucose production in the fetus,
which is most likely related to AMPK activation [68]. Other authors have evaluated the
anti-hyperglycemic and anti-teratogenic capacity of maternal resveratrol (100 mg/kg/d
from gestational days 8 to 12, when neurulation occurs) in a streptozotocin-induced diabetic
Wistar rat model. They found that, on the 19th gestational day, resveratrol ameliorated
the oxidative stress produced in the fetus by maternal hyperglycemia, and thus showing
embryo-protective properties [65]. These studies evaluated the short-term effects of mater-
nal resveratrol on the fetus or embryo in diabetic rodent models, showing favorable results
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on metabolic homeostasis and redox state. However, the offspring’s longer-term outcome
and whether there were differences between the sexes are not specified (Table 1).
The effects of maternal resveratrol on metabolic parameters at weaning have also been
analyzed. In 2017 Zou et al. reported that resveratrol supplementation (0.2%) in HFD-fed
dams (C57BL/6J mice) during pregnancy and lactation protected against the harmful effects
of maternal HFD on white adipose browning and thermogenesis in male offspring at wean-
ing, accompanied by persistent beneficial effects in the protection against HFD-induced
obesity and metabolic disorders [66]. We used a Wistar rat model where dams received
a low-fat diet (LFD; 10.2% Kcal from fat) or HFD (61.6% Kcal from fat) during gestation
and lactation to determine the effect of maternal resveratrol intake (2–2.5 mg/kg/day
in drinking water) during pregnancy and lactation on the metabolism of the offspring
at weaning and observed that these effects depend on the type of diet ingested by the
mother and the offspring’s sex [30]. Of note, we used a low dose of resveratrol that can
be easily ingested in a normal diet and based on its described hormetic property [24,69].
We found that resveratrol decreased body weight (BW) and adipose tissue (visceral and
subcutaneous) mass at weaning in offspring from HFD-fed dams but had no effect on these
parameters in the offspring from LFD-fed dams. This finding suggests that the potential
protective effects of resveratrol during gestation/lactation may be maternal diet-dependent.
This observation could be due to the fact that, as stated above, the effect of resveratrol is
related to its interaction with the cellular redox state. Moreover, we found that female
offspring were more globally affected by maternal resveratrol intake than males [30].
Long-lasting effects of maternal resveratrol on the offspring have also been reported.
In Sprague Dawley rats, Liu Ta-Yu and colleagues investigated the effects of resveratrol,
administered in drinking water (50 mg/L), and maternal HFD intake on the progeny
and the response to postnatal HFD intake. They reported that on PND140, maternal
resveratrol intake reduced lipogenesis and adiposity, increased lipolysis and ameliorated
leptin resistance in male progeny [69]. They also found that maternal resveratrol protected
against the maternal high-fat/high-sucrose-induced decrease in SIRT1 mRNA levels in
retroperitoneal adipose tissue and normalized the plasmatic leptin/sOB-R ratio of the
offspring. We recently reported that some of the metabolic changes that we observed at
weaning are maintained in the adult offspring, and that they remain sex and maternal
diet-dependent. Maternal resveratrol intake reduced serum cholesterol levels in both male
and female adult offspring from HFD mothers, but increased it in adult female offspring
from mothers consuming a LFD. Resveratrol also increased visceral adipose tissue (VAT) in
maternal LFD offspring of both sexes but decreased it in male offspring from mothers on a
HFD. Interestingly, maternal resveratrol intake shifted the distribution of VAT adipocyte
size to a significantly higher incidence of large adipocytes, regardless of sex or maternal
diet [31], suggesting an effect on adipocyte development. Liu Ta-Yu reported a decrease
in visceral adipocyte size in 4-month-old male progeny from dams fed a HFHSD plus
resveratrol [69]. In Sprague Dawley rats, maternal resveratrol supplementation (50 mg/L
in drinking water, from pregnancy to lactation) is also reported to reduce the maternal
HFD-induced retroperitoneal adiposity and the increase in leptin/sOB-R ratio in adult
male offspring, while no data in females were reported. However, they found no effect of
resveratrol on SIRT1 expression in the retroperitoneal adipose tissue of these animals [13].
Long-lasting effects of maternal resveratrol intake during only lactation (20 mg/kg/day),
have been recently reported [67]. Maternal resveratrol consumption during lactation in
dams fed a normal control diet was found to decrease plasma cholesterol levels in the
male offspring at PND 273, through suppression of hepatic cholesterol biosynthesis and
promotion of hepatic cholesterol uptake. Furthermore, a decrease in hepatic 3-hydroxy-3-
methylglutaryl-CoA reductase and an increase in hepatic LDL receptor levels were also
observed in the maternal resveratrol male offspring [67].
Maternal protein restriction during pregnancy is a well-established early life under-
nutrition model that is known to increase both maternal and offspring oxidative stress,
leading to metabolic dysfunction. Vega et al. demonstrated that maternal resveratrol in-
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take (20 mg/kg/day throughout pregnancy) partially prevented low-protein diet-induced
maternal, placental and offspring oxidative stress and metabolic dysfunction at PND 110.
They also showed sex differences in the modifications of triglyceride levels, liver reactive
oxygen species (ROS) and fat depots in the offspring [29]. Taken together, studies in ro-
dents suggest metabolic benefits of maternal resveratrol consumption in the offspring (i.e,
decreased cholesterol levels, lipogenesis, adiposity, leptin resistance). However, to date
differences in experimental protocols have led to inconclusive results.
Studies in non-human primates have also shown placental and fetal benefits in re-
sponse to resveratrol supplementation when the mother is on a Western diet (36% calories
from fat) during pregnancy. In an experimental model employing Japanese macaques,
Roberts and colleagues [62] reported that supplementation with resveratrol during preg-
nancy (final concentration of 0.37% in a Western diet, from 3 months before the breeding
season until gestational day 130) increased uterine artery blood flow volume and decreased
placental inflammation and fetal liver triglyceride deposition. However, fetal pancreatic
mass was found to be enlarged by 42%, with a 12-fold increase in proliferation as demon-
strated by Ki67 immunohistochemistry [62]. This same group showed that consumption of
a Western-style diet during pregnancy impaired offspring islet vascularization in Japanese
macaques. Furthermore, when dams were put on a normal healthy diet, islet vascular-
ization was normalized to control offspring levels, whereas resveratrol supplementation
caused a significant increase in capillary density above controls [63]. These authors stated
that due to the observed alterations in fetal pancreatic development and, until the long-term
consequences of increased vascularization can be determined, resveratrol supplementation
during pregnancy is not advised [62,63]. Indeed, although resveratrol has shown to be well
tolerated in experimental animals with no major adverse effects, several studies reported
that resveratrol could exert toxic effects, especially at high doses (≥50 mg/kg) [70]. Using
Japanese macaques, O’Tierney-Ginn and colleagues studied the in utero influence of resver-
atrol (0.37% incorporated in the food) on the effects of HFD (35% fat) consumption prior to
and throughout pregnancy on fatty acid uptake in placental explants. At gestational day
130 (term = 173 days), resveratrol stimulated placental DHA uptake capacity, AMPK activa-
tion and mRNA levels of fatty acid transporter protein 4, FATP-4, scavenger receptor CD36
and fatty acid binding protein [64]. These findings suggest that resveratrol could protect
placental fatty acid uptake capacity and AMPK activity, a nutrient-sensing target, from the
negative effects of maternal HFD. In summary, studies analyzing maternal resveratrol in
non-human primates have shown an improvement in artery blood flow volume, placental
inflammation and fetal liver triglyceride deposition along with a potential protective role
against HFD.
3.2. Human Studies
Although the evidence in humans is limited, specific effects of resveratrol have been
reported in ex vivo human placenta and adipose tissue samples [71,72]. Lappas et al.
investigated the effects of resveratrol at different concentrations (50, 100 and 200 µmL/L)
on insulin resistance and placental inflammation associated with gestational diabetes. They
reported that at a concentration of 200 µmL/L, resveratrol is able to decrease placental
inflammation as the expression of the pro-inflammatory cytokines tumor necrosis factor
(TNF), interleukin (IL)-6 and 8 were reduced [71]. This same group also found that resvera-
trol (200 µmL/L) significantly reduced the expression of IL-6 and IL-8 in ex vivo human
omental adipose tissue and placenta [72].
To our knowledge, limited human studies have analyzed the effects of resveratrol
intake during pregnancy and lactation but none of them analyzed the offspring’s health
outcome [73,74]. In these two studies resveratrol was used as an adjuvant treatment in
pregnant women. Malvasi et al. used resveratrol in addition to D-chiro-inositol and
myo-inositol in overweight pregnant women with an elevated fasting glucose, finding an
improvement in glucose levels, LDL cholesterol and triglycerides [73]. On the other hand,
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Ding and colleagues analyzed the effect of resveratrol as an adjuvant treatment of oral
nifedipine to attenuate hypertensive symptoms [74].
4. Sex Differences in Response to Perinatal Changes
We know that males and females have metabolically different responses not only to
early nutritional changes [75] but also to stressful conditions during early life [76,77] and
that the sexually dimorphic responses to these early interventions often vary according to
age [75,76]. However, much is yet to be learned about the long-term differences between
males and females in response to early nutritional changes as many studies have only been
performed in one sex, and this is normally males. To our knowledge, only three studies
analyzing the effects of maternal resveratrol have focused on sex differences. Vega et al.
showed clear sex differences in the response to maternal resveratrol intake as decreased
triglycerides and liver ROS was observed in male but not in female offspring of low-protein
diet-fed dams, with no effects in those on a control diet [29]. Ros et al. found sex differences
in both the short- and long-term responses to an unbalanced maternal diet with or without
resveratrol. At weaning, a decrease in BW, leptin and fat depots was observed in the
offspring from HFD dams plus resveratrol when compared to those from HFD mothers,
with females being more affected by resveratrol than males [30]. Maternal resveratrol
intake was also found to decrease the visceral fat depot, but only in adult male offspring
from HFD mothers [31].
5. Conclusions
Collectively, these studies indicate an effect of maternal resveratrol intake on the
offspring. Although the mechanism of action of resveratrol is not completely understood,
it has been hypothesized that it can induce epigenetic modifications. It is important to
emphasize that the beneficial effects of resveratrol as a therapeutic intervention may be
affected by many factors, such as the baseline health status of the subjects, nutritional
habits, resveratrol dose and the intervention period. Although resveratrol is reported to
be well tolerated and safe, caution must be exerted as abnormal pancreatic development
and vascularization has also been reported in the offspring of non-human primate mothers
consuming resveratrol. However, different study designs and objectives, as well the large
variability in the dose, route and timetable of resveratrol administration, make it difficult
to reach robust conclusions about the health benefits of resveratrol before considering it
for human therapeutic use during pregnancy and/or lactation. In addition, the evidence
concerning offspring outcome remains scarce even in animal models and some of these
studies have been performed only in males. This is of great importance, as we know that
the effects of early nutritional modifications can be sex-specific and data to date indicate
that the response to early resveratrol also varies according to sex. Therefore, further and
more homogeneous studies are needed to determine how resveratrol exposure during
gestation and lactation affects long-term health with both the sex-specific responses and
the type of diet ingested taken into consideration.
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